Prospective, multi-center post-marketing surveillance cohort study to monitor the safety of the human papillomavirus-16/18 AS04-adjuvanted vaccine in Chinese girls and women aged 9 to 45 years, 2018

Prospective, multi-center post-marketing surveillance cohort study to monitor the safety of the human papillomavirus-16/18 AS04-adjuvanted vaccine in Chinese girls and women aged 9 to 45 years, 2018–2020

Published:2023-12 Issue:3 Volume:19 Page:
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Wu Qianhui¹,Qian Mengcen¹²,Welby Sarah³,Guignard Adrienne³,Rosillon Dominique³,Gopala Kusuma⁴,Xu Yuan⁵,Liu Keruo⁶,He Yunkun⁶,Jiang Ning⁶,Tan Qin⁷,Xie Jiamin⁷,Zhu Taoying⁸,Wang Qizhang⁹,Pan Yingzi¹⁰,Zeng Ruikun¹¹,Yang Jie¹²,Zhao Xiaoqian¹³,Zhou Man¹⁴,Navarro-Torné Adoración³,Yu Hongjie¹¹⁵¹⁶^ORCID,Borys Dorota³

Affiliation:

1. Key Laboratory of Public Health Safety, Ministry of Education, Fudan University, Shanghai, China

2. Key Laboratory of Health Technology Assessment, Ministry of Health, Fudan University, Shanghai, China

3. GSK, Wavre, Belgium

4. GSK, Bangalore, India

5. GSK, Wuhan, China

6. GSK, Shanghai, China

7. Shunde District Center for Disease Control and Prevention, Guangdong, China

8. Wuhou District Center for Disease Control and Prevention, Sichuan, China

9. Pudong New Area Center for Disease Control and Prevention, Shanghai, China

10. Wujin District Center for Disease Control and Prevention, Jiangsu, China

11. Longgang District Center for Disease Control and Prevention, Guangdong, China

12. Luohu District Center for Disease Control and Prevention, Guangdong, China

13. Taocheng District Center for Disease Control and Prevention, Hebei, China

14. Xicheng District Center for Disease Control and Prevention, Beijing, China

15. Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China

16. Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China

Funder

GlaxoSmithKline Biologicals

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2023.2283912

Reference37 articles.

1. Bruni L Albero G Serrano B Mena M Collado JJ Gómez D Muñoz J Bosch FX de Sanjosé S. Human papillomavirus and related diseases in the world. ICO/IARC information centre on HPV and cancer (HPV Information Centre). 2021 [accessed 2022 Mar 15]. https://hpvcentre.net/statistics/reports/XWX.pdf.

2. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis

3. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study

4. Human papillomavirus vaccines. WHO position paper;World Health Organization;Wkly Epidemiol Rec,2009